Flubromazolam’s function in medical trials is limited due to its classification for a designer drug. Nevertheless, its results happen to be reversed through the benzodiazepine antagonist flumazenil in pharmacokinetic experiments, furnishing insights into its clinical implications and emergency management of overdoses.No spontaneous involuntary o
Article Under Review
Article Under Review